George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
News|Articles|June 3, 2026
4 Nephrology Headlines You Missed in May 2026
Author(s)Alex Hillenbrand
Fact checked by: Abigail Brooks, MA
Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.
Advertisement
Advertisement
May 2026 brought significant developments across
Related to this article
Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.
A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.
Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Advertisement
Advertisement